Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy.
作者信息
Longcor Jarrod, Callander Natalie, Oliver Kate, Chanan-Khan Asher, Ailawadhi Sikander
机构信息
Cellectar Biosciences, Inc., Florham Park, NJ, USA.
University of Wisconsin Carbone Cancer Center, Madison, WI, USA.
出版信息
Blood Cancer J. 2022 Sep 6;12(9):130. doi: 10.1038/s41408-022-00725-2.
Abstract
摘要
相似文献
1
Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy.I-131 碘磷法辛治疗抗 BCMA 免疫治疗后复发/难治性多发性骨髓瘤的晚期患者。
Blood Cancer J. 2022 Sep 6;12(9):130. doi: 10.1038/s41408-022-00725-2.
2
Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.靶向多发性骨髓瘤中的 B 细胞成熟抗原（BCMA）：基于 BCMA 的免疫疗法的潜在用途。
Front Immunol. 2018 Aug 10;9:1821. doi: 10.3389/fimmu.2018.01821. eCollection 2018.
3
Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.BCMA 靶向 CAR-T 免疫疗法治疗多发性骨髓瘤和复发性/难治性多发性骨髓瘤概述。
Scand J Immunol. 2020 Aug;92(2):e12910. doi: 10.1111/sji.12910. Epub 2020 Jun 17.
4
Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.抗 BCMA CAR-T 细胞疗法在伴有髓外疾病的复发/难治性多发性骨髓瘤患者中的应用：两项临床试验的单中心分析。
Front Immunol. 2021 Oct 29;12:755866. doi: 10.3389/fimmu.2021.755866. eCollection 2021.
5
Subsequent anti-myeloma therapy after maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) treatment in patients with relapsed/refractory multiple myeloma.复发/难治性多发性骨髓瘤患者接受成熟抗原（BCMA）嵌合抗原受体（CAR）-T细胞（HDS269B）治疗后的后续抗骨髓瘤治疗。
Am J Hematol. 2022 Dec;97(12):E478-E481. doi: 10.1002/ajh.26745. Epub 2022 Oct 17.
6
IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model.分泌白细胞介素-18 的多抗原靶向嵌合抗原受体 T 细胞在免疫功能正常的小鼠模型中消除低抗原骨髓瘤。
Blood. 2024 Jul 11;144(2):171-186. doi: 10.1182/blood.2023022293.
7
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.经基因修饰表达抗 B 细胞成熟抗原嵌合抗原受体的 T 细胞可引起预后不良的复发性多发性骨髓瘤缓解。
J Clin Oncol. 2018 Aug 1;36(22):2267-2280. doi: 10.1200/JCO.2018.77.8084. Epub 2018 May 29.
8
BCMA-targeted immunotherapy for multiple myeloma.BCMA 靶向免疫疗法治疗多发性骨髓瘤。
J Hematol Oncol. 2020 Sep 17;13(1):125. doi: 10.1186/s13045-020-00962-7.
9
Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.人源化抗 BCMA CAR T 细胞疗法在有和无髓外疾病的复发/难治性多发性骨髓瘤患者中的疗效。
Front Immunol. 2021 Aug 5;12:720571. doi: 10.3389/fimmu.2021.720571. eCollection 2021.
10
BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma.BCMA CAR-T 疗法联合泊马度胺是治疗复发/难治性多发性骨髓瘤的一种安全有效的方法。
J Transl Med. 2024 Nov 29;22(1):1087. doi: 10.1186/s12967-024-05772-w.
引用本文的文献
1
Safety and toxicity of Iopofosine I 131 (CLR 131) with external beam radiation therapy in recurrent or metastatic head and neck cancer: results of a phase 1 single-centre, open-label, single-arm, dose escalation and dose expansion study.131碘-碘磷腈（CLR 131）联合外照射放疗用于复发性或转移性头颈癌的安全性和毒性：一项1期单中心、开放标签、单臂、剂量递增和剂量扩展研究的结果
EBioMedicine. 2025 Jan;111:105496. doi: 10.1016/j.ebiom.2024.105496. Epub 2024 Dec 12.
2
Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy.BCMA 嵌合抗原受体 T 细胞治疗后复发的多发性骨髓瘤患者的机制和挽救治疗。
Front Immunol. 2024 Oct 22;15:1433774. doi: 10.3389/fimmu.2024.1433774. eCollection 2024.
3
Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia.新型方法治疗复发/难治性华氏巨球蛋白血症患者。
Curr Hematol Malig Rep. 2024 Aug;19(4):163-174. doi: 10.1007/s11899-024-00730-1. Epub 2024 Jul 6.
4
Clinical Advances and Perspectives in Targeted Radionuclide Therapy.靶向放射性核素治疗的临床进展与展望
Pharmaceutics. 2023 Jun 14;15(6):1733. doi: 10.3390/pharmaceutics15061733.
5
Targeting of Head and Neck Cancer by Radioiodinated CLR1404 in Murine Xenograft Tumor Models with Partial Volume Corrected Theranostic Dosimetry.放射性碘标记 CLR1404 通过部分体积校正治疗剂量学靶向头颈部癌的鼠异种移植肿瘤模型。
Cancer Biother Radiopharm. 2023 Sep;38(7):458-467. doi: 10.1089/cbr.2022.0084. Epub 2023 Apr 5.
6
CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies.嵌合抗原受体 T 细胞疗法在多发性骨髓瘤中的应用：当前的局限性与潜在策略。
Front Immunol. 2023 Feb 20;14:1101495. doi: 10.3389/fimmu.2023.1101495. eCollection 2023.
本文引用的文献
1
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee.复发/难治性多发性骨髓瘤治疗中的差距和机遇：NCI 多发性骨髓瘤指导委员会的共识建议。
Blood Cancer J. 2022 Jun 29;12(6):98. doi: 10.1038/s41408-022-00695-5.
2
Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results.多发性骨髓瘤患者临床试验之外：真实世界结果的批判性综述
Front Oncol. 2022 May 11;12:844779. doi: 10.3389/fonc.2022.844779. eCollection 2022.
3
Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis.复发/难治性多发性骨髓瘤患者接受idecabtagene vicleucel治疗后的后续抗骨髓瘤治疗：单中心分析
Blood Cancer J. 2022 Apr 19;12(4):66. doi: 10.1038/s41408-022-00662-0.
4
Targeted treatment of multiple myeloma with a radioiodinated small molecule radiopharmaceutical.用放射性碘化小分子放射性药物对多发性骨髓瘤进行靶向治疗。
Leuk Lymphoma. 2021 Jun;62(6):1518-1521. doi: 10.1080/10428194.2021.1876858. Epub 2021 Jan 27.
5
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.贝兰他单抗马妥昔单抗治疗复发或难治性多发性骨髓瘤（DREAMM-2）：一项双臂、随机、开放标签、2 期研究。
Lancet Oncol. 2020 Feb;21(2):207-221. doi: 10.1016/S1470-2045(19)30788-0. Epub 2019 Dec 16.
6
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.口服塞利尼索联合地塞米松治疗三药难治性多发性骨髓瘤。
N Engl J Med. 2019 Aug 22;381(8):727-738. doi: 10.1056/NEJMoa1903455.
7
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.抗 BCMA CAR T 细胞疗法 bb2121 治疗复发/难治性多发性骨髓瘤。
N Engl J Med. 2019 May 2;380(18):1726-1737. doi: 10.1056/NEJMoa1817226.
8
Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications.嵌合抗原受体 T 细胞免疫疗法治疗多发性骨髓瘤：当前数据和潜在临床应用的综述。
Am J Hematol. 2019 May;94(S1):S28-S33. doi: 10.1002/ajh.25428. Epub 2019 Feb 25.
9
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma.一项针对复发或难治性多发性骨髓瘤患者的靶向 B 细胞成熟抗原嵌合抗原受体 T 细胞疗法 LCAR-B38M 的 1 期、开放性研究。
J Hematol Oncol. 2018 Dec 20;11(1):141. doi: 10.1186/s13045-018-0681-6.
10
Multiple myeloma epidemiology and survival: A unique malignancy.多发性骨髓瘤的流行病学与生存率：一种独特的恶性肿瘤。
Semin Oncol. 2016 Dec;43(6):676-681. doi: 10.1053/j.seminoncol.2016.11.004. Epub 2016 Nov 10.
Zotero 插件